Fenselau

396 views

Published on

University of Maryland Baltimore
Experimental Therapeutics Symposium 2009

Published in: Education, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
396
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Fenselau

  1. 1. <ul><li>Mechanisms by which tumors resist therapy </li></ul><ul><li>Rapid pathogen identification using mass spectrometry </li></ul><ul><li>Techniques used: proteomics, bioinformatics </li></ul><ul><li>Funding: GM021248; CA126189 </li></ul><ul><li>Collaborations: UMBC, Georgetown Med, Hopkins APL </li></ul>Catherine Fenselau’s research
  2. 2. <ul><li>The plasma membrane is of special interest </li></ul><ul><li>Disease Biomarkers </li></ul><ul><li>Drug Resistance Mechanisms </li></ul><ul><li>Targets for new drugs </li></ul><ul><li>70% of Current Drug Targets are membrane Proteins </li></ul><ul><li>90% of Drugs in Development target membrane proteins </li></ul>
  3. 3. Left: Scheme of a nanoparticle pellicle process. Nanoparticles allow plasma membrane proteins to be isolated with higher selectivity and enrichment. Right: Micrograph showing purified membrane fragments coated with cationic silica nanobeads. (Stolz et al 1999).
  4. 4. Scheme of a novel nanoparticle pellicle process. Heavy metal nanowires will allow plasma membrane proteins to be isolated with higher selectivity and enrichment, accomplished by higher resistance to endocytosis and reinforced interactions between nanowire and cell membrane by multiple binding events.
  5. 5. Myeloma derived suppressor cells promote the growth of tumors Prof. S. Ostrand-Rosenberg, UMBC
  6. 6. <ul><li>Our working hypothesis is that plasma membrane receptors on MDSC are essential for MDSC binding to target cells and for activation of the MDSC. </li></ul><ul><li>Receptors will be identified, using novel proteomic technology. Functional confirmation will be carried out in Dr. Ostrand-Rosenberg’s laboratory, using mice implanted with a mouse mammary carcinoma that shares many characteristics with human breast cancer </li></ul>

×